FRAMINGHAM (03/22/2004) - Life is good at GenPath Pharmaceuticals Inc. right now. Last October, the company raised US$42.7 million in a Series B round and was awarded a patent (#6,639,121) for its inducible cancer technology. In December, it landed a mega deal with Merck that could ultimately be worth $100 million. The company's star-studded advisory board includes MIT Nobel laureate Bob Horvitz; Richard Klausner, former head of the National Cancer Institute; Tyler Jacks, head of the MIT Center for Cancer Research; and Ed Scolnick, president emeritus of Merck. And its VC lineup is no less stellar.
- Free Whitepaper! The 5 criteria to help you select the right analytics platform for your organization.
- Free Whitepaper! Learn how to create an analytics environment that is governed, scalable and self-serve.
- Free Whitepaper! Learn how IT is evolving from producer to enabler, and fostering collaboration around analytics.